ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This national pediatric IBD network aims to collect clinical data and biological samples to study causes of early-onset IBD, track outcomes including intestinal healing and growth, and improve treatment strategies — work that could inform future prevention, diagnostics, and personalized care for children with IBD.
Who Should Pay Attention
Pediatric patients with IBD and their caregivers; pediatric gastroenterologists and clinical teams; researchers focused on genetics, microbiome, and biomarkers; patient advocacy groups.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment2,400 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN) is an observational, prospective inception cohort and biobank enrolling Canadian children and adolescents with IBD to study why pediatric IBD develops and to evaluate best treatment strategies.
The project will collect clinical data, demographic and lifestyle information, and biological samples (biobank) for long-term storage so future genetic, microbiome, and biomarker research can be performed.
The network will follow approximately 2,400 participants from diagnosis until transfer to adult care and use REDCap for centralized data capture and quality control. The Network emphasizes multi-site governance, training, and processes for data integrity. Access to stored samples or data for future studies will require committee and REB review.
The coordinating centre is at The Hospital for Sick Children (SickKids) in Toronto.
Keep In Mind
The record describes study design, goals, cohort size (~2400) and infrastructure (biobank, REDCap, national coordinating centre). It does not report results; future research proposals using the biobank will require REB approval.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorThe Hospital for Sick Children
Trial IDNCT02308917
Study typeObservational
Enrollment2,400 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedOct 9, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The exposome and inflammatory bowel disease: a framework for primary and primordial prevention
The exposome perspective emphasizes that many non-genetic, potentially modifiable environmental factors likely influence IBD risk. Understanding these factors could help guide prevention research and public-health...
Gut Microbiota, Inflammatory Bowel Disease and the Prioritization of Host Effector Genes: A Two-Sample Mendelian Randomization Study with Independent Replication, cis-eQTL Colocalization and Single-Cell Localization
The work suggests specific host genes and cell types that might mediate links between gut microbes and IBD, which could direct future laboratory research into mechanisms and potential biomarkers.
From signals to systems: the epigenetic-microbiome-mitochondrial axis in IBD pathogenesis.
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...